Dechra’s Zygolide adds first generic pergolide option for PPID

Dechra’s Zygolide is now entering the U.S. equine market as the first FDA-approved generic pergolide tablet for horses with pituitary pars intermedia dysfunction, better known as PPID or equine Cushing’s disease. FDA approved the product on December 19, 2025, then publicly announced the decision on January 9, 2026, confirming that Zygolide is bioequivalent to Prascend, the long-standing brand-name pergolide product first approved in 2011. (animaldrugsatfda.fda.gov)

That matters because pergolide is the mainstay medical therapy for PPID, a common endocrine disorder in older horses that requires long-term, often lifelong, management. The category has historically had limited FDA-approved options, and the market has long been shaped by the need for careful titration, repeat endocrine testing, and practical workarounds when horses resist medication. FDA’s older enforcement history around compounded pergolide also underscores why an additional approved product could be meaningful for prescribers and pet parents alike. (aaep.org)

Dechra announced the approval on January 5, 2026, describing Zygolide as a first-to-market generic, peppermint-flavored pergolide tablet available through veterinarians and major online pharmacies. The company is emphasizing three differentiators: cost relief, a flavored formulation, and a 1 mg tablet with 360-degree scoring to simplify splitting. FDA and Dechra materials also make clear that the product is prescription-only and intended for oral use in horses. (dechra-us.com)

The regulatory file adds useful detail beyond the promotional messaging. FDA’s freedom of information summary says the abbreviated approval relied on a 24-horse in vivo blood-level bioequivalence study comparing Zygolide with Prascend. Product labeling states dosing is calculated to the nearest half tablet, not to exceed 4 mcg/kg daily. In Dechra’s cited effectiveness data, 76.1% of 113 evaluable horses were treatment successes at Day 180, and 41.6% required a dose increase at Day 90, a reminder that PPID control often requires reassessment rather than a set-and-forget prescription. (animaldrugsatfda.fda.gov)

Safety and handling remain part of the clinical conversation. FDA says tablets should not be crushed because splitting or crushing pergolide tablets may increase human exposure and has been associated with eye irritation, odor, or headache. The label also says treatment may cause inappetence, with decreased appetite reported in 40 of 122 horses in the six-month field study safety analysis, and notes that the product has not been evaluated in breeding, pregnant, or lactating horses. (fda.gov)

Direct outside expert reaction to Zygolide itself appears limited so far, but the broader PPID literature points to the same pressure points Dechra is trying to address. Coverage of compliance research in treated PPID horses has highlighted how administration challenges and day-to-day adherence can affect laboratory control, while AAEP and university guidance continue to frame pergolide as the treatment of choice, paired with regular monitoring of ACTH and clinical signs. In that sense, the product’s flavoring and scored-tablet design are best understood as adherence tools, not a change in therapeutic mechanism. (equimanagement.com)

Why it matters: For veterinary professionals, Zygolide could modestly change the economics and workflow of PPID management even if the pharmacology is familiar. A generic option may help keep more horses on labeled therapy, especially those needing higher doses over time. It may also give veterinarians another way to respond when pet parents struggle with tablet administration or monthly medication costs. But the clinical fundamentals stay the same: diagnosis still depends on appropriate endocrine testing, treatment still requires titration and follow-up, and palatability alone won’t solve underdosing, poor monitoring, or cases complicated by insulin dysregulation and laminitis risk. (dechra-us.com)

What to watch: The next signals will be real-world pricing, formulary adoption by equine practices and pharmacies, and whether the product’s administration features lead to measurable gains in adherence or persistence compared with existing pergolide use. (dechra-us.com)